Company introduction
OWL Genomics is a biotechnology company founded in 2002 with the mission to contribute to the solution of important problems in the field of human health that present serious deficiencies in diagnosis and treatment. OWL Genomics was born upon the knowledge and scientific developments of Dr. Jose Maria Mato, founding partner and Scientific Director of the company.
The activity of the company is centered in the area of human health, with pioneering applications in the international scientific panorama, and whose objective is to identify, validate, patent and commercialize diagnostic and/or prognostic systems, as well as therapeutic targets involved in the development of complex diseases.
To consolidate the developments of OWL Genomics as a technology-based company, an innovative line of development has been carried out, Metabolomics, which allows opening diagnostics to the massive identification of specific biomarkers for a given pathology. It is a state of the art technology that combines ultra performance liquid chromatography with mass spectrometry, and that allows OWL Genomics to offer a novel metabolomics service, with potential clients in hospitals, research centers, and biotechnology and pharmaceutical industries.
Thus, OWL has established a leading position in personalized medicine for liver disease, specifically, non-alcoholic steatohepatitis (NASH) and is currently introducing the first in vitro serum based diagnostic for NAFLD and NASH, based on the studies carried out by Dr. José María Mato during the last twenty five years on hepatic diseases.
The current clinical diagnosis for NASH is based on liver biopsy, an invasive and costly procedure. The company has developed a simple blood test to be used for NASH diagnosis. An early diagnosis seems to be the best way to stop the progression of the disease by changing their life style and monitoring patient evolution.
Besides, OWL Genomics has qualified professionals to complete and develop present and future new research lines in a wide range of pathologies, offering a variety of innovative products of excellence.
Since its foundation OWL has obtained full support from biotechnology group Cross Road Biotech, (its main share holder). They have brought their management skills and biotechnology business knowledge.
On the other hand the leading position of OWL Genomics would not have been possible without an important network of collaborators, for which a number of strategic alliances with biotechnology and bioinformatics companies, hospitals, research centers and universities has been formed.
Julián Sánchez
CEO
Azucena Castro
General Manager